Avoro Capital Advisors LLCAvoro Capital Advisors LLC

Institutional investor · Portfolio as of Q1 2022

Top Holdings43 positions

Checking export access…
Activity:

HORIZON THERAPEUTICS PLC

6.5M$683.9M12.5%——
12 qtrssince 2019-Q2
Decreased
0

UNITED THERAPEUTICS CORP DEL

3M$543.6M9.9%$150.28+16.87%
6 qtrssince 2020-Q4
Decreased
0
APLSAPLSDelisted

APELLIS PHARMACEUTICALS INC

9.5M$480.2M8.8%$41.55+19.06%
5 qtrssince 2021-Q1
Increased
68
MRTXMRTXDelisted

MIRATI THERAPEUTICS INC

5.3M$437.8M8.0%——
13 qtrssince 2019-Q1
Increased
65
ARGXARGX
ADR

ARGENX SE

1.3M$395.7M7.2%$183.06+72.24%
13 qtrssince 2019-Q1
Increased
77
XBIXBI
ETF

SPDR SERIES TRUST

3.1M$274.1M5.0%$97.93-7.89%
2 qtrssince 2021-Q4
Increased
98
ASNDASND
ADR

ASCENDIS PHARMA A/S

2.2M$258.2M4.7%$133.46-13.07%
4 qtrssince 2021-Q2
Increased
63

SAREPTA THERAPEUTICS INC

3.1M$244.9M4.5%$104.42-24.73%
13 qtrssince 2019-Q1
Increased
57

BIOMARIN PHARMACEUTICAL INC

3M$234M4.3%$84.99-8.35%
13 qtrssince 2019-Q1
Increased
62

ALNYLAM PHARMACEUTICALS INC

1.3M$212.3M3.9%$166.65-0.85%
4 qtrssince 2021-Q2
Increased
68
FOLDFOLDDelisted

AMICUS THERAPEUTICS INC

20.5M$194.1M3.5%$11.15-13.84%
13 qtrssince 2019-Q1
Increased
63
SGENSGENDelisted

SEAGEN INC

1.3M$189.4M3.5%——
1 qtr
New
85

XENON PHARMACEUTICALS INC

5M$152.4M2.8%$17.33+73.84%
13 qtrssince 2019-Q1
Unchanged
0

IOVANCE BIOTHERAPEUTICS INC

9.1M$151.9M2.8%$15.23+9.64%
13 qtrssince 2019-Q1
Increased
56

MADRIGAL PHARMACEUTICALS INC

1.4M$139.8M2.6%$117.61-16.57%
13 qtrssince 2019-Q1
Unchanged
0
ISEEISEEDelisted

IVERIC BIO INC

7.3M$122M2.2%——
8 qtrssince 2020-Q2
Unchanged
0

KURA ONCOLOGY INC

4.8M$77.2M1.4%$26.02-38.16%
8 qtrssince 2020-Q2
Increased
57

KRYSTAL BIOTECH INC

1M$66.9M1.2%$68.60-2.48%
2 qtrssince 2021-Q4
Increased
76

ACADIA PHARMACEUTICALS INC

2.3M$55.1M1.0%$46.77-58.14%
6 qtrssince 2020-Q4
Increased
49

MONTE ROSA THERAPEUTICS INC

3.3M$46.4M0.8%$19.98-32.18%
4 qtrssince 2021-Q2
Unchanged
0
$5.5B
AUM
43
Positions
Q1 2022
Filing
HI score · 2.5/5
Quarterly 13F Value Change
-18%Q4'20$5.8B-0%Q1'21$5.8B-1%Q2'21$5.7B+11%Q3'21$6.4B-8%Q4'21$5.9B-7%Q1'22$5.5B
Activity profile
$ moved · Q1'22
New15%Increased51%Decreased27%Exited7%
Composition
Equity vs derivatives
Equity100%Puts0%Calls0%
Holding period
Avg 1.6 years
<1Q9%1-4Q21%1-2Y33%2Y+37%

Avoro Capital Advisors LLC manages $5.5B across 43 positions as of Q1 2022. Top holdings: HZNP (12.5%), UTHR (9.9%), APLS (8.8%). Fund DNA: Concentrated Value. HoldingsIntel Score: 2.5/5.0.

Q1 2022 Summary

Added 4 new positions, exited 1, increased 20, trimmed 4. Top move: XBI (INCREASED, conviction 98). Portfolio: $5.5B across 43 positions.

Top holdings by portfolio weight

Total AUM$5B
HZNP12.48%
UTHR9.92%
APLS8.77%
MRTX7.99%
ARGX7.22%
XBI5.00%
ASND4.71%
SRPT4.47%
BMRN4.27%
ALNY3.88%
Other3.54%

Portfolio allocation by GICS sector

Sectors2
Healthcare66.82%
Unknown33.18%

Behavioral investing profile

Checking access…
Concentrated Value- primarily Healthcare, Unknown
Compare DNA across all funds
7-dimension, SEC 13F-derived research score
Solid(2.5 / 5.0)
Holdings P&L53
Conviction47
Concentration100
Checking access…

Position Outcomes

Best and worst performing positions by estimated return

Cost basis estimates based on full filing history using quarter-end prices. Actual transaction prices are not disclosed in 13F filings.

Similar Funds

Funds with similar investing DNA

Accumulation Streaks

Positions with 2+ consecutive quarters of increases - persistent directional conviction.

Security
4Q
OCULOCULOCULAR THERAPEUTIX INC
Q3 2025 → Q2 2026+5.1M shares+$54.5M
3Q
UTHRUTHRUNITED THERAPEUTICS CORP DEL
Q4 2025 → Q2 2026+755,555 shares+$657.3M
2Q
ARWRARWRARROWHEAD PHARMACEUTICALS IN
Q1 2026 → Q2 2026+730,555 shares+$220.2M
Checking access…

Data sourced from SEC EDGAR 13F filings. Not financial advice. Full disclaimer

Verify source filings on SEC EDGAR

Analytics tracking helps us improve the product. Essential functions stay on either way. How analytics data is used